Multiple drug resistance (MDR), defined as the ability of tumour cells to survive exposure to many chemotherapeutic agents, is a major cause of treatment failure in human cancers. The membrane transporter P-glycoprotein (Pgp, encoded by the ABCB1 [adenosine triphosphate-binding cassette, subfamily B, member 1] gene) is the main mechanism for decreased intracellular drug accumulation in human MDR cancer. ABCB1/Pgp-mediated MDR involves several signal transduction pathways and transcription factors. Activation of these signal transduction pathways influences the prognosis of MDR human cancer. Signalling pathways involved in ABCB1/Pgp-mediated MDR include the mitogen-activated protein kinase (MAPK), c-Jun NH2-terminal kinase (JNK), p38, cyclic adenosine monophosphate-dependent protein kinase, phosphatidylinositol 3-kinase and protein kinase C signalling pathways. This review summarizes the biological characteristics, target points and signalling cascade mediators of these pathways. Drugs targeted against these pathways may provide new therapies for treatment of ABCB1/Pgp-mediated MDR.
BaguleyBC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol2010; 46: 308–316.
3.
SandorVFojoTBatesSE: Future perspectives for the development of P-glycoprotein modulators. Drug Resist Updat1998; 1: 190–200.
4.
NakagamiHSoukupováHSchikoraA: A Mitogen-activated protein kinase kinase kinase mediates reactive oxygen species homeostasis in Arabidopsis. J Biol Chem2006; 281: 38697–38704.
5.
KisuckáJBarancíkMBohácováV: Reversal effect of specific inhibitors of extracellular-signal regulated protein kinase pathway on P-glycoprotein mediated vincristine resistance of L1210 cells. Gen Physiol Biophys2001; 20: 439–444.
6.
DurajJZazrivcovaKBodoJ: Flavonoid quercetin, but not apigenin or luteolin, induced apoptosis in human myeloid leukemia cells and their resistant variants. Neoplasma2005; 52: 273–279.
7.
WeiNSunHWangF: H1, a novel derivative of tetrandrine reverse P-glycoprotein-mediated multidrug resistance by inhibiting transport function and expression of P-glycoprotein. Cancer Chemother Pharmacol2011; 67: 1017–1025.
8.
HungCCLiouHH: YC-1, a novel potential anticancer agent, inhibit multidrug-resistant protein via cGMP-dependent pathway. Invest New Drugs2011; 29: 1337–1346.
9.
WestonCRDavisRJ: The JNK signal transduction pathway. Curr Opin Genet Dev2002; 12: 14–21.
10.
LagadinouEDZirosPGTsopraOA: c-Jun N-terminal kinase activation failure is a new mechanism of anthracycline resistance in acute myeloid leukemia. Leukemia2008; 22: 1899–1908.
11.
ZhangYZhouJXuW: JWA sensitizes P-glycoprotein-mediated drug-resistant choriocarcinoma cells to etoposide via JNK and mitochondrial-associated signal pathway. J Toxicol Environ Health A2009; 72: 774–781.
12.
BarkHChoiCH: PSC833, cyclosporine analogue, downregulates MDR1 expression by activating JNK/c-Jun/AP-1 and suppressing NF-κB. Cancer Chemother Pharmacol2010; 65: 1131–1136.
13.
OsbornMTChambersTC: Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs. J Biol Chem1996; 271: 30950–30955.
14.
ComerfordKMCumminsEPTaylorCT: c-Jun NH2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia. Cancer Res2004; 64: 9057–9061.
15.
SuiHZhouSWangY: COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer. Carcinogenesis2011; 32: 667–675.
16.
HanJLeeJDBibbsL: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science1994; 265: 808–811.
17.
BarancíkMBohácováVKvackajováJ: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur J Pharm Sci2001; 14: 29–36.
18.
LiYLiSHanY: Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur J Pharmacol2008; 591: 252–258.
19.
JiaoJWWenF: Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells. Oncol Rep2011; 25: 781–788.
20.
LingXHeXApontesP: Enhancing effectiveness of the MDR-sensitive compound T138067 using advanced treatment with negative modulators of the drug-resistant protein survivin. Am J Transl Res2009; 1: 393–405.
21.
RohlffCGlazerRI: Regulation of multidrug resistance through the cAMP and EGF signalling pathways. Cell Signal1995; 7: 431–443.
22.
ZiemannCRieckeARüdellG: The role of prostaglandin E receptor-dependent signaling via cAMP in Mdr1b gene activation in primary rat hepatocyte cultures. J Pharmacol Exp Ther2006; 317: 378–386.
23.
PacoldMESuireSPerisicO: Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ. Cell2000; 103: 931–943.
24.
KuoMTLiuZWeiY: Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-κB signaling. Oncogene2002; 21: 1945–1954.
25.
McCubreyJASteelmanLSAbramsSL: Roles of the RAF/MEK/ERK and PI3K/PTENs/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul2006; 46: 249–279.
26.
WangYQuYNiuXL: Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine2011; 56: 365–375.
27.
KaszubiakAKupstatAMüllerU: Regulation of MDR1 gene expression in multidrug-resistant cancer cells is independent from YB-1. Biochem Biophys Res Commun2007; 357: 295–301.
28.
OdaYKohashiKYamamotoH: Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci2008; 99: 726–732.
29.
KeniryMParsonsR: The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene2008; 27: 5477–5485.
30.
MaehamaTDixonJE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem1998; 273: 13375–13378.
31.
LeeSChoiEJJinC: Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol2005; 97: 26–34.
32.
JiDDeedsSLWeinsteinEJ: A screen of shRNAs targeting tumor suppressor genes to identify factors involved in A549 paclitaxel sensitivity. Oncol Rep2007; 18: 1499–1505.
33.
SafeSAbdelrahimM: Sp transcription factor family and its role in cancer. Eur J Cancer2005; 41: 2438–2448.
34.
OkaMKounouraKNarasakiF: P-glycoprotein is positively correlated with p53 protein accumulation in human colorectal cancers. Jpn J Cancer Res1997; 88: 738–742.
35.
MatsuhashiNSaioMMatsuoA: The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anticancer drugs. Oncol Rep2005; 14: 609–615.
36.
RimlerAJockersRLupowitzZ: Differential effects of melatonin and its downstream effector PKCα on subcellular localization of RGS proteins. J Pineal Res2006; 40: 144–152.
37.
FineRLPatelJChabnerBA: Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA1988; 85: 582–586.
38.
BlobeGCSachsCWKhanWA: Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF-7 cells. Functional significance of enhanced expression of PKC α. J Biol Chem1993; 268: 658–664.
39.
GekelerVBoerRIseW: The specific bisindolylmaleimide PKC-inhibitor GF 1 09 203X efficiently modulates MRP-associated multiple drug resistance. Biochem Biophys Res Commun1995; 206: 119–126.
40.
BergmanPJGravittKRWardNE: Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Invest New Drugs1997; 15: 311–318.
41.
BrüggerDBrischweinKLiuC: Induction of drug resistance and protein kinase C genes in A2780 ovarian cancer cells after incubation with antineoplastic agents at sublethal concentrations. Anticancer Res2002; 22: 4229–4232.
42.
ZhangHJiangHSunFRapid diagnosis of multidrug resistance in cancer by electrochemical sensor based on carbon nanotubes—drug supramolecular nano-composites. Biosens Bioelectron2011; 26: 3361–3366.
43.
OzbenT: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett2006; 580: 2903–2909.
44.
AmbudkarSVDeySHrycynaCA: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol1999; 39: 361–398.
45.
StavrovskayaAA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc)2000; 65: 95–106.
DeanMRzhetskyAAllikmetsR: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res2001; 11: 1156–1166.
48.
ChildsSLingV: The MDR superfamily of genes and its biological implications. In: Important Advances in Oncology (DeVitaVTHellmanSRosenbergSA eds). Philadelphia: Lippincott, 1994; pp 21–36.
49.
de VriesEFDoorduinJVellingaNA: Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study. Nucl Med Biol2008; 35: 459–466.
50.
Cordon-CardoCO'BrienJPBocciaJ: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem1990; 38: 1277–1287.
51.
KlappeKHummelIHoekstraD: Lipid dependence of ABC transporter localization and function. Chem Phys Lipids2009; 161: 57–64.
52.
ChenCJChinJEUedaK: Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell1986; 47: 381–389.
53.
VasconcelosFCSilvaKLSouzaPS: Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients. Cytometry B Clin Cytom2011; 80: 158–166.
54.
CizmarikovaMWagnerovaMSchonovaL: MDR1 (C3435T) polymorphism: relation to the risk of breast cancer and therapeutic outcome. Pharmacogenomics J2010; 10: 62–69.
55.
MiltenbergerRJFarnhamPJSmithDE: v-Raf activates transcription of growth-responsive promoters via GC-rich sequences that bind the transcription factor Sp1. Cell Growth Differ1995; 6: 549–556.
56.
KimSHLeeSHKwakNH: Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett1996; 98: 199–205.
57.
MerkleDHoffmannR: Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal2011; 23: 507–515.
58.
MisraUKPizzoSV: Epac1-induced cellular proliferation in prostate cancer cells is mediated by B-Raf/ERK and mTOR signaling cascades. J Cell Biochem2009; 108: 998–1011.
59.
LeoneVdi PalmaARicchiP: PGE2 inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest Liver Physiol2007; 293: G673–G681.
60.
WongKKEngelmanJACantleyLC: Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev2010; 20: 87–90.
61.
KikkawaUAseKOgitaK: The role of protein kinase C in cell surface signal transduction and tumor promotion. Gan To Kagaku Ryoho1986; 13: 861–869 [in Japanese, English abstract].
62.
MelisiDChiaoPJ: NF-κB as a target for cancer therapy. Expert Opin Ther Targets2007; 11: 133–144.
63.
HienTTKimHGHanEH: Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-κB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res2010; 54: 918–928.
64.
ZhouGKuoMT: NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem1997; 272: 15174–15183.
65.
OgretmenBSafaAR: Negative regulation of MDR1 promoter activity in MCF-7, but not in multidrug resistant MCF-7/Adr, cells by cross-coupled NF-κB/p65 and c-Fos transcription factors and their interaction with the CAAT region. Biochemistry1999; 38: 2189–2199.
66.
WangWMcLeodHLCassidyJ: Disulfiram-mediated inhibition of NF-κB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer2003; 104: 504–511.
67.
SzlosarekPWBalkwillFR: Tumour necrosis factor α: A potential target for the therapy of solid tumours. Lancet Oncol2003; 4: 565–573.
68.
SethuSMelendezAJ: New developments on the TNFα-mediated signalling pathways. Biosci Rep2011; 31: 63–76.
69.
D'AlessandroNFlugyATolomeoMThe apoptotic signaling of TNF-α in multidrug resistant Friend leukemia cells. Anticancer Res1998; 18: 3065–3072.
70.
GarcíaMGAlanizLLopesECInhibition of NF-κB activity by BAY 11–7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res2005; 29: 1425–1434.
71.
GuttridgeDCMayoMWMadridLV: NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science2000; 289: 2363–2366.
72.
UzohCCPerksCMBahlA: PTEN-mediated pathways and their association with treatment-resistant prostate cancer. BJU Int2009; 104: 556–561.
73.
LeeJTJrSteelmanLSMcCubreyJA: Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res2004; 64: 8397–8404.
74.
KohnoKTanimuraHSatoSCellular control of human multidrug resistance 1 (mdr-1) gene expression in absence and presence of gene amplification in human cancer cells. J Biol Chem1994; 269: 20503–20508.
75.
YuanHYoungCYTianYSuppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells. Mol Cell Biochem2010; 339: 253–262.
